⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Figure S9 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Kunling Chen Huolun Feng Yujie Zhang Jingyuan Pei Yuyan Xu Xiangxu Wei Zhuohao Chen Zhoubin Feng Lei Cai Yong Li Liang Zhao Mingxin Pan

View at Publisher

Ask AI

Bookmark

Share

Key Points

CCL16 treatment significantly improves tumor vasculature normalization and immunotherapy response in HCC.
Elevated macrophage ICAM-1 levels correlate with enhanced efficacy of immunotherapy in hepatocellular carcinoma models.
The study employed experimental models to investigate the impact of CCL16 on the tumor immune microenvironment in HCC.
Findings indicate that targeting CCL16 may offer new therapeutic strategies for improving outcomes in HCC patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Research reveals that CCL16 enhances immunotherapy efficacy by normalizing tumor vasculature in HCC, suggesting critical roles for macrophage ICAM-1.

Abstract

The effect of CCL16 on the TIME and tumor vasculature in HCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21b0d https://doi.org/10.1158/0008-5472.30254920

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
2Figure S1 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
3Figure S6 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
4Figure S8 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
5Figure S7 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025

Figure S5 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
Data from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
Table S1 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025